Blue Jet Healthcare Ltd (NSE: BLUEJET, BSE: 544009) is a Thane, Maharashtra-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹10,140 Cr, it ranks #587 by market cap among the 6,197 Indian listed companies on FinBizNet, and #9 of 11 in Pharmaceutical CDMO and CRO Services. At ₹540.55 (as of 16 Nov 2026), the share price is 16.6% below its 52-week high of ₹647.80 and 66.3% above its 52-week low of ₹325.00. The share price is down 9.8% over one year and down 9.3% over three months.
| Current Price | ₹540.55 |
|---|---|
| Market Cap | ₹10,140 Cr |
| NSE Symbol | BLUEJET |
| BSE Code | 544009 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 38 |
| Return on Equity | 19.88% |
| Return on Assets | 11.24% |
| 52-Week Range | ₹325.00 – ₹647.80 |
| 1-Year Price Change | -9.8% |
| 3-Month Price Change | -9.3% |
| Beta (1Y) | 0.7 |
| Dividend Yield | 0.22% |
| Headquarters | Thane, Maharashtra |
| Website | www.bluejethealthcare.com |
| Revenue | ₹376 Cr |
|---|---|
| Net Profit | ₹103 Cr |
| Net Margin | 27.3% |
| EPS (Basic) | ₹5.46 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Blue Jet Healthcare Ltd reported revenue of ₹376 Cr in Q2 FY27, up 127.1% from ₹165 Cr in Q2 FY26 and up 28.2% from ₹293 Cr in Q1 FY27. It posted a net profit of ₹103 Cr for the quarter, against a net profit of ₹52 Cr in Q2 FY26 (up 96.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹165 Cr (Q2 FY26) to ₹376 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹376 Cr | ₹103 Cr | 27.3% |
| Q1 FY27 | ₹293 Cr | ₹78 Cr | 26.7% |
| Q4 FY26 | ₹235 Cr | ₹64 Cr | 27.4% |
| Q3 FY26 | ₹192 Cr | ₹40 Cr | 20.9% |
| Q2 FY26 | ₹165 Cr | ₹52 Cr | 31.5% |
| Q1 FY26 | ₹355 Cr | ₹91 Cr | 25.7% |
| Q4 FY25 | ₹340 Cr | ₹110 Cr | 32.3% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 73.15% of Blue Jet Healthcare Ltd's shares as of Sept 2026, against 79.81% in Dec 2025 (−6.66 percentage points). Delivery averaged 48.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
1. Generic Formulation Business-This segment engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. It also engages in contract manufacturing business.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹3,01,758 Cr | 118.4 | 16.19% | ₹3,676 Cr | +71.9% |
| Anthem Biosciences Limited | ₹53,926 Cr | 90.1 | 19.45% | ₹594 Cr | +34.5% |
| Sai Life Sciences Limited | ₹40,755 Cr | 116.1 | 15.13% | ₹659 Cr | +120.3% |
| Onesource Specialty Pharma Limited | ₹18,138 Cr | n/m | -1.26% | ₹516 Cr | -9.4% |
| Cohance Lifesciences Ltd | ₹17,756 Cr | 100.6 | 5.11% | ₹477 Cr | -35.2% |
| Syngene International Ltd. | ₹17,630 Cr | 56.9 | 6.62% | ₹833 Cr | -27.9% |
| Jubilant Pharmova Ltd | ₹15,556 Cr | 39.1 | 5.96% | ₹2,370 Cr | -14.5% |
| Concord Biotech Ltd | ₹12,495 Cr | 24.2 | 13.54% | ₹309 Cr | -14.8% |
| Blue Jet Healthcare Ltd | ₹10,140 Cr | 38 | 19.88% | ₹376 Cr | -9.8% |
Listed by market capitalisation. Ratios are shown for context only.
Blue Jet Healthcare Ltd is trading at ₹540.55, with a market capitalisation of ₹10,140 Cr.
Blue Jet Healthcare Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Blue Jet Healthcare Ltd has a P/E of 38 and a return on equity of 19.88%.
Blue Jet Healthcare Ltd is listed on the NSE under the symbol BLUEJET and on the BSE under the scrip code 544009.
Blue Jet Healthcare Ltd's share price is down 9.8% over one year and down 9.3% over three months. Its 52-week range is ₹325.00 to ₹647.80.
In Q2 FY27, Blue Jet Healthcare Ltd reported revenue of ₹376 Cr and net profit of ₹103 Cr, with basic EPS of ₹5.46 (standalone, parsed from the company's exchange filing).
Blue Jet Healthcare Ltd reported revenue of ₹376 Cr in Q2 FY27, up 127.1% from ₹165 Cr in Q2 FY26 and up 28.2% from ₹293 Cr in Q1 FY27.
Promoters held 73.15% of Blue Jet Healthcare Ltd's shares as of Sept 2026, against 79.81% in Dec 2025 (−6.66 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.